Home LiteratureArticle Details
PMID: 2647123 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial.

The British journal of dermatology ·Vol. 120 ·No. 2 ·1989-02-00 ·Pages 267-75

Rustin MH, Newton JA, Smith NP, Dowd PM

Abstract

A pilot study, a double-blind placebo-controlled randomised study and a long term open trial have indicated that nifedipine is effective in the treatment of perniosis. At a dose of 20 mg to 60 mg daily, nifedipine significantly reduced the time to clearance of existing lesions and prevented the development of new chilblains. Nifedipine also reduced the pain, soreness and irritation of the lesions. A comparison of the pre- and post-treatment skin biopsies showed resolution of the dermal oedema and diminution of the perivascular infiltrate. An increase in cutaneous blood flow following administration of nifedipine suggests that the vasodilator action of this drug may be important in its action.

MeSH Terms
Adolescent Adult Aged Chilblains/drug therapy Clinical Trials as Topic Double-Blind Method Female Frostbite/drug therapy Humans Male Middle Aged Nifedipine/therapeutic use Pilot Projects Random Allocation
Chemicals
Nifedipine
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Rustin M H
Department of Dermatology, Middlesex Hospital, London, U.K.
Newton J A
Smith N P
Dowd P M
Article Info
Journal
The British journal of dermatology
Abbr.
Br J Dermatol
ISSN
0007-0963
Published
1989-02-00
Pages
267-75
Language
English
Region
England
NLM ID
0004041
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com